JAZZ PHARMACEUTICALS FRANCE

Jazz Pharmaceuticals' Board of Directors unanimously selected Renee Gala as President and CEO, effective August 11, 2025, succeeding co-founder Bruce Cozadd who will remain as Board Chairperson.

Xenon Pharmaceuticals has appointed Darren Cline as Chief Commercial Officer to lead commercial strategy for azetukalner, the company's lead Phase 3 candidate targeting epilepsy, major depressive disorder, and bipolar depression.

China's National Medical Products Administration granted conditional approval to zanidatamab for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, marking the first dual HER2-targeted bispecific antibody approved for this indication in China.

Phase 3 trial results reveal that combining Zepzelca with Tecentriq as maintenance therapy extended median progression-free survival to 5.4 months versus 2.1 months with Tecentriq alone in metastatic small cell lung cancer patients.

Komodo Health's healthcare intelligence platform enabled 31 research studies presented at the 2025 ISPOR global conference, including three studies led by Komodo researchers and 27 collaborative studies with academic institutions and Life Sciences companies.

Amgen's tarlatamab (Imdelltra) demonstrated superior overall survival compared to standard chemotherapy in relapsed small cell lung cancer patients, potentially establishing a new second-line treatment standard.

• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively. • The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results. • Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.

The U.S. Court of Appeals for the Federal Circuit has overturned key portions of a Delaware Court injunction, allowing Avadel Pharmaceuticals to seek FDA approval for LUMRYZ in idiopathic hypersomnia.

PharmaMar has applied for accelerated assessment from the European Medicines Agency for lurbinectedin in combination with Roche's Tecentriq (atezolizumab) for extensive-stage small cell lung cancer.

Actuate Therapeutics will present Phase II clinical trial data on elraglusib, their GSK-3β inhibitor, for advanced salivary gland carcinoma at the AACR Annual Meeting 2025 in Chicago.